drugset / Trial / NCT05737368
Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With Cadonilimab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness in the treatment of recurrent glioblastoma with Cadonilimab combined with fractionated radiotherapy.
Timeline
- Start
- 2023-02-28
- Primary completion
- 2024-02-28
- Completion
- 2025-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | — |